Login / Signup

The Effectiveness of Risankizumab Following Guselkumab Failure in Moderate-to-Severe Psoriasis Patients: A Retrospective Study.

Camille HammNusha RamsoondarMichaela McGillisMiranda WaughMelinda J GooderhamLyne L Giroux
Published in: Journal of cutaneous medicine and surgery (2023)
Our findings reflect an improvement in sPGA scores when patients are treated with risankizumab following guselkumab failure. This highlights the benefit of in-class switch to risankizumab when patients with moderate-to-severe plaque psoriasis have failed multiple treatments including guselkumab.
Keyphrases